A PYMNTS Company

Amgen-Micromet merger gets HSR early termination

 |  February 16, 2012

Amgen and Micromet have announced early termination of the Hart-Scott-Rodino waiting period by the FTC. Amgen seeks to acquire Micromet with a tender offer for common stock at $11 per share in cash. Amgen is a biotechnology firm involved in human therapeutics; Micromet is a biopharmaceutical company for antibody-based therapies in cancer treatment.

Source: MarketWatch


Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)